Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Am Heart J. 2010 Dec;160(6):1163–1169. doi: 10.1016/j.ahj.2010.08.002

Table 4.

Risk of Cardiovascular Disease According to FTO Genotype Risk Categories and Physical Activity Level

>8.8 MET-hours/week 8.8 MET-hours/week

Low-Risk Medium-Risk High-Risk Low-Risk Medium-Risk High-Risk
C/C A/C A/A C/C A/C A/A
N 3,913 5,173 1,755 3,863 5,230 1,740

Mean BMI, kg/m2 (±SD) 24.84 (4.22) 24.89 (4.17) 25.57 (4.73) 26.31 (5.03) 26.90 (5.45) 27.82 (5.86)

No. of Events 104 107 52 131 186 84

Crude Model 1.0 0.78 (0.60–1.03) 1.13 (0.81–1.57) 1.34 (1.04–1.73) 1.39 (1.09–1.76) 1.91 (1.44–2.55)
 P-value 0.08 0.48 0.03 0.008 <0.0001
Model 1* 1.0 0.78 (0.58–1.05) 1.06 (0.73–1.54) 1.14 (0.86–1.52) 1.22 (0.93–1.58) 1.83 (1.34–2.50)
 P-value 0.10 0.75 0.37 0.15 0.0001
Model 2 1.0 0.79 (0.59–1.05) 1.01 (0.70–1.46) 1.06 (0.79–1.41) 1.09 (0.84–1.42) 1.54 (1.13–2.11)
 P-value - 0.10 0.96 0.71 0.52 0.007
Model 3 1.0 0.78 (0.59–1.05) 1.02 (0.70–1.47) 1.04 (0.77–1.38) 1.04 (0.79–1.36) 1.49 (1.09–2.05)
 P-value - 0.10 0.94 0.82 0.77 0.01

Crude model adjusted for age and randomized treatment assignment.

*

Model 1: crude model additionally adjusted for alcohol use, caloric intake, saturated fat and fiber intake, smoking, and parental history of myocardial infarction.

Model 2: Model 1, additionally adjusted for BMI and BMI2.

Model 3: Model 2, additionally adjusted for cholesterol lowering medication, total cholesterol, LDL-C, HDL-C, TG, hsCRP, menopausal status, post-menopausal hormone therapy, hypertension, diabetes and the metabolic syndrome.